Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

695 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 228
Recruiting: 123
Ph III recruiting: 18
Growth YoY: +39.5%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (82)

clinicaltrialsPublishedShowing 251–280 of 280 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05177133	Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus)	recruiting	Phase 2	25	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER	1	Aug 2, 2024	clinicaltrials
NCT04554771	Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy(BASALT)	active not recruiting	Phase 2	41	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)